AU2001272028A1 - Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin - Google Patents

Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin

Info

Publication number
AU2001272028A1
AU2001272028A1 AU2001272028A AU7202801A AU2001272028A1 AU 2001272028 A1 AU2001272028 A1 AU 2001272028A1 AU 2001272028 A AU2001272028 A AU 2001272028A AU 7202801 A AU7202801 A AU 7202801A AU 2001272028 A1 AU2001272028 A1 AU 2001272028A1
Authority
AU
Australia
Prior art keywords
egf
composition
skin
tyrosine kinase
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272028A
Other languages
English (en)
Inventor
Gary J. Fisher
John J Voorhees
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of AU2001272028A1 publication Critical patent/AU2001272028A1/en
Priority to AU2006246530A priority Critical patent/AU2006246530A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
AU2001272028A 2000-06-26 2001-06-26 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin Abandoned AU2001272028A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006246530A AU2006246530A1 (en) 2000-06-26 2006-12-04 Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21394000P 2000-06-26 2000-06-26
US60/213,940 2000-06-26
PCT/US2001/041154 WO2002000183A2 (en) 2000-06-26 2001-06-26 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin

Publications (1)

Publication Number Publication Date
AU2001272028A1 true AU2001272028A1 (en) 2002-01-08

Family

ID=22797119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272028A Abandoned AU2001272028A1 (en) 2000-06-26 2001-06-26 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin

Country Status (8)

Country Link
US (2) US20020012641A1 (pt)
EP (1) EP1294349A2 (pt)
JP (1) JP2004504276A (pt)
AU (1) AU2001272028A1 (pt)
BR (1) BR0112355A (pt)
CA (1) CA2414406A1 (pt)
MX (1) MXPA03000089A (pt)
WO (1) WO2002000183A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516873A (en) * 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2542007C (en) * 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
JP2005263645A (ja) * 2004-03-16 2005-09-29 Shiseido Co Ltd 炎症を抑制する方法及び組成物
US20080119530A1 (en) * 2006-09-29 2008-05-22 Hansen Laura A Method for treatment and prevention of ultraviolet light induced skin pathologies
JP5746807B2 (ja) * 2006-12-28 2015-07-08 アルロン・ジャパン株式会社 皮膚用化粧品の組成物
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US20080269339A1 (en) * 2007-04-26 2008-10-30 Thomas Robert Sutter Combined use of egf pathway inhibitors and differentiation promoting compounds
WO2009051434A1 (en) * 2007-10-17 2009-04-23 Biocare Co., Ltd. Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same
CN101918037A (zh) * 2007-11-15 2010-12-15 通用医疗公司 用于减少皮肤损伤的方法和组合物
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
US20110020477A1 (en) * 2008-03-31 2011-01-27 Shiseido Company, Ltd. Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles
WO2009122540A1 (ja) * 2008-03-31 2009-10-08 株式会社資生堂 しわを防止または改善するための経口、注射、皮膚外用剤および美容方法
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
KR102200014B1 (ko) * 2013-05-06 2021-01-08 (주)아모레퍼시픽 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
US5824702A (en) * 1996-06-07 1998-10-20 Mount Sinai School Of Medicine Of The City University Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
WO1998010767A2 (en) * 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
IL131543A (en) * 1997-02-25 2005-08-31 Univ Michigan Cosmetic methods and compositions for preventing and treating chronological aging in human skin
DE19713092A1 (de) * 1997-03-27 1998-10-01 Wacker Chemie Gmbh Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
TWI234455B (en) * 1998-04-02 2005-06-21 Univ Michigan Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin
FR2782919B1 (fr) * 1998-09-04 2001-05-25 Roc Sa Composition contre le vieillissement et son utilisation
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
JP2001039849A (ja) * 1999-07-27 2001-02-13 Shiseido Co Ltd コラーゲン産生促進剤

Also Published As

Publication number Publication date
WO2002000183A3 (en) 2002-07-25
EP1294349A2 (en) 2003-03-26
CA2414406A1 (en) 2002-01-03
US20020012641A1 (en) 2002-01-31
WO2002000183A2 (en) 2002-01-03
MXPA03000089A (es) 2004-09-13
BR0112355A (pt) 2005-04-19
US20050281764A1 (en) 2005-12-22
JP2004504276A (ja) 2004-02-12

Similar Documents

Publication Publication Date Title
US20050281764A1 (en) Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin
CA2281944C (en) Methods and compositions for preventing and treating chronological aging in human skin
JP3705820B2 (ja) 皮膚の光老化を抑制する方法
Parvez et al. Survey and mechanism of skin depigmenting and lightening agents
US6942870B2 (en) Compositions and methods using direct MMP inhibitors for inhibiting photoaging of skin
KR101089071B1 (ko) 백모증 처리를 위한 엘라그산의 용도
KR100930257B1 (ko) 백모증 처리를 위한, 3ｈ-1,2-디티올-3-티온, 아네톨 디티올에티온, 설포라판, 펜에틸 이소티오시아네이트, 6-(메틸설피닐)헥실 이소티오시아네이트 및 알릴 이소티오시아네이트의 용도
MXPA01006891A (es) Composiciones de soya para el cuidado y despigmentacion de la piel.
Wertz et al. β-carotene inhibits UVA-induced matrix metalloprotease 1 and 10 expression in keratinocytes by a singlet oxygen-dependent mechanism
Mammone et al. Modification of skin discoloration by a topical treatment containing an extract of Dianella ensifolia: a potent antioxidant
KR100953848B1 (ko) 백모증 치료를 위한, 쿠마린 및 그의 유도체, 부틸화하이드록시아니솔 및 에톡시퀸의 용도
AU2006246530A1 (en) Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin
Welsh et al. Topical all-trans retinoic acid augments ultraviolet radiation-induced increases in activated melanocyte numbers in mice
Padmavathi et al. Efficacy of Topical Soy Isoflavonoid Extract in Prevention and Reversal of Photo-Ageing in Guinea Pig Model
AU701132C (en) Method of inhibiting photoaging of skin
KR100352687B1 (ko) 광노화를예방하기위한화장품
Godic SKIN PHOTOAGING AND THE ROLE OF ANTIOXIDANTS IN ITS PREVENTION
AU2002301116B2 (en) Compositions and Methods for Inhibiting Photoaging of Skin
Tanaka et al. Current status of whitening agents and their future in Japan
MXPA99007883A (es) Metodos y composiciones para prevernir y tratar el envejecimiento cronológico en la piel humana
KR20040066375A (ko) 미백용 실리콘중수형 또는 오일중수형 메이크업 화장료조성물

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted